Open AccessMyogenic progenitor cells derived from human induced pluripotent stem cell are immune‐tolerated in humanized mice
Author(s) -
Benabdallah Basma,
DésaulniersLangevin Cynthia,
Goyer MarieLyn,
Colas Chloé,
Maltais Chantale,
Li Yuanyi,
Guimond Jean V.,
Tremblay Jacques P.,
Haddad Elie,
Beauséjour Christian
Publication year - 2021
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.19-0452
Subject(s) - induced pluripotent stem cell , reprogramming , stem cell , progenitor cell , immune system , immunology , biology , humanized mouse , cell therapy , adoptive cell transfer , haematopoiesis , microbiology and biotechnology , peripheral blood mononuclear cell , cancer research , t cell , cell , in vitro , embryonic stem cell , biochemistry , genetics , gene
It is still unclear if immune responses will compromise the large‐scale utilization of human induced pluripotent stem cells (hiPSCs)‐derived cell therapies. To answer this question, we used humanized mouse models generated by the adoptive transfer of peripheral blood mononuclear cells or the cotransplantation of hematopoietic stem cells and human thymic tissue. Using these mice, we evaluated the engraftment in skeletal muscle of myoblasts derived either directly from a muscle biopsy or differentiated from hiPSCs or fibroblasts. Our results showed that while allogeneic grafts were mostly rejected and highly infiltrated with human T cells, engraftment of autologous cells was tolerated. We also observed that hiPSC‐derived myogenic progenitor cells (MPCs) are not targeted by autologous T cells and natural killer cells in vitro. These findings suggest that the reprogramming and differentiation procedures we used are not immunogenic and that hiPSC‐derived MPCs will be tolerated in the presence of a competent human immune system.